Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2004

Conditions

Heart Failure, Congestive

Interventions

DRUG

KW-3902IV

Trial Locations (10)

Stanford

Washington D.C.

Sarasota

Baltimore

Ayer

Boston

Newark

Philadelphia

Charleston

Tullahoma

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00159627 - Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF). | Biotech Hunter | Biotech Hunter